Optimization of 3D ZnO brush-like nanorods for dye-sensitized solar cells

In a dye-sensitized solar cell (DSSC) the amount of adsorbed dye on the photoanode surface is a key factor that must be maximized in order to obtain enhanced DSSC performance. In this study 3D ZnO nanostructures, named brush-like, are demonstrated as alternative photoanodes. In these structures, long ZnO nanorods are covered with a metal–organic precursor, known as a layered-hydroxide zinc salt (LHZS), which is subsequently converted to crystalline ZnO using two-step annealing. The LHZS is able to easily grow on any surface, such as the ZnO nanorod surface, without needing the assistance of a seed-layer. Brush-like structures synthesized using different citrate concentrations in the growth solutions and different annealing conditions are characterized and tested as DSSC photoanodes. The best-performing structure reported in this study was obtained using the highest citrate concentration (1.808 mM) and the lowest temperature annealing condition in an oxidative environment. Conversion efficiency as high as 1.95% was obtained when these brush-like structures were employed as DSSC photoanodes. These results are extremely promising for the implementation of these innovative structures in enhanced DSSCs, as well as in other applications that require the maximization of surface area exposed by ZnO or similar semiconductors, such as gas- or bio-sensing or photocatalysis.

Optimized 3D ZnO brush-like nanorods showing large surface area are presented as the photoanode in enhanced high-current-density DSSCs.     

A human cell-based assay to evaluate the effects of alterations in the MLH1 mismatch repair gene

We describe a new approach to investigate alterations in the human MLH1 mismatch repair (MMR) gene. This is based on complementation of the phenotype of a MLH1-defective subclone of the ovarian carcinoma A2780 cells by transfection of vectors encoding altered MLH1 proteins. Measurements of resistance (tolerance) to methylating agents, mutation rate at HPRT, microsatellite instability (MSI), and steady-state levels of DNA 8-oxoguanine were used to define the MMR status of transfected clones. The approach was validated by transfecting cDNA of wild-type (WT) MLH1, cDNAs bearing two previously identified polymorphisms (I219V and I219L) and two with confirmed hereditary nonpolyposis colorectal cancer (HNPCC) syndrome mutations (G224D and G67R). A low-level expression of two MLH1 polymorphisms partially reversed methylation tolerance and the mutator phenotype, including MSI. Higher levels of I219V resulted in full restoration of these properties to WT. Increased expression of I129L did not fully complement the MLH1 defect, because there was a simultaneous escalation in the level of oxidative DNA damage. The findings confirmed the important relationship between deficient MMR and increased levels of oxidative DNA damage. Mutations from Italian HNPCC families (G224D, G67R, N635S, and K618A) were all ineffective at reversing the phenotype of the MLH1-defective A2780 cells. One (K618A) was identified as a low penetrance mutation based on clinical and genetic observations.     

Genetically driven CD39 expression shapes human tumor-infiltrating CD8+ T-cell functions

In our study, we investigated the role of CD39 on tumor-infiltrating CD8⁺ T lymphocytes (CD8⁺ TILs) in colorectal, head and neck and pancreatic cancers. Partially confirming recent observations correlating the CD39 expression with T-cell exhaustion, we demonstrated a divergent functional activity in CD39⁺CD8⁺ TILs. On the one hand, CD39⁺CD8⁺ TILs (as compared to their CD39⁻ counterparts) produced significantly lower IFN-γ and IL-2 amounts, expressed higher PD-1, and inversely correlated with perforin and granzyme B expression. On the other, they displayed a significantly higher proliferative capacity ex vivo that was inversely correlated with the PD-1 expression. Therefore, CD39⁺CD8⁺ TILs, including those co-expressing the CD103 (a marker of T resident memory [TRM] cells), were defined as partially dysfunctional T cells that correlate with tumor patients with initial progression stages. Interestingly, our results identified for the first time a single nucleotide polymorphism (SNP rs10748643 A>G), as a genetic factor associated with CD39 expression in CD8⁺ TILs. Finally, we demonstrated that compounds inhibiting CD39-related ATPases improved CD39⁺CD8⁺ T-cell effector function ex vivo, and that CD39⁺CD8⁺ TILs displayed effective suppression function in vitro. Overall these data suggest that the SNP analysis may represent a suitable predictor of CD39⁺CD8⁺ T-cell expression in cancer patients, and propose the modulation of CD39 as a new strategy to restore partially exhausted CD8⁺ TILs.